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BACKGROUND: The pattern of allelic loss of heterozygosity (LOH) and PTEN mutations appear to be
associated with the progression of gliomas leading to a decrement in the survival rate of patients. This
present study was carried out to determine the LOH and PTEN mutational status in glioma patients and
its association with patients’ survival.
METHODS: Thirty-seven Malaysian glioma patients of the Malay race were subject to PTEN mutational
analysis and the presence of LOH using the cold single-strand conformation polymorphism method, and
their clinical and paraclinical response were correlated.
RESULTS: Among analysed glioma patients, seven (21.6%) cases with PTEN mutations were detected and
12 (32.4%) of 37 patients showed presence of LOH. Univariate analysis showed that tumour grade, vascu-
larization, PTEN mutation, LOH and combination of both PTEN mutation and LOH were significantly
associated with glioma patients’ survival. Multivariate analysis revealed that no factors contributed to
survival time.
CONCLUSION: The results show that PTEN mutation and LOH are quite frequent in Malaysian glioma
patients. However, they have no impact on the survival outcome of patients. [Asian J Surg 2006;29(4):
274–82]
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Introduction
Malignant gliomas are the most common primary tumours
of the brain.1 The reported number of glioma cases in
Malaysia are on the rise and has been increasing steadily over
the years.2 Over the decades, brain tumours, in particular
glioblastoma multiforme (GBM), have retained their dismal
prognosis despite advances in neurosurgical techniques,
radiation and drug therapies. In particular, malignant GBM
have defied all current therapeutic modalities. Gene therapy
offers the potential to augment current neurosurgical, radi-
ation and drug treatments with little increase in morbidity.3
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The current interest in molecular genetics is to study
the relationship between genetic alterations and how they
contribute to the presenting illness, clinical and paraclin-
ical findings as well as therapy and outcome.
Genetic alterations, which were continuously reported
at high frequency in a variety of human tumours, includ-
ing gliomas are loss of heterozygosity (LOH) at chromo-
some 10q23 and PTEN mutation. Loss of functional
PTEN from tumour cells causes accumulation of critical
second messenger lipids, leading to decreased apoptosis
and/or increased mitogen signalling.5
Frequent allelic losses were reported in malignant
astrocytoma, glioblastoma, anaplastic oligodendroglioma
and ependymoma cases. In malignant astrocytoma, regu-
lar allelic losses were defined in chromosomes 10, 13q,
17p and 22q, suggesting the presence of tumour suppres-
sor genes on these chromosomes.6 They have also reported
LOH cases on chromosome 17p in anaplastic oligoden-
droglioma samples. LOH on chromosomes 10 and 13q
was found in most anaplastic ependymoma cases. While
in glioblastomas, with partial loss of chromosome 10, 
at least three common deletions were found which are
10q14-pter, 10q23-24 and 10q25-qter, suggestive of mul-
tiple tumour suppressor genes.6,7 Forty to sixty percent 
of reported deletions in glioblastoma cases occur on 
chromosome 9p21.8
Several studies have shown that LOH as well as PTEN
mutation are correlated with poor prognosis in glioma
patients.5,9,10 They suggested that by losing function of
those regions, the survival rates of the patients decreased.
The aim of this prospective study was to determine the
relationship of PTEN mutation and LOH in gliomas of 
a group of Malaysian patients in relation to their clinical,
radiological and pathological documentation response to
therapy, as well as the survival time of the patients.
Patients and methods
Thirty-seven patients were studied over a period of 36
months. Parameters such as age, sex, classification of the
tumours and presenting complaints such as headache,
hemiplegia, epilepsy as well as radiological images, i.e. site,
size, consistency of tumour, midline shift and vascularity,
were compared with their management, PTEN mutation,
LOH status, relapse rate and outcome. Social groups were
divided into economic upper class (> US$250), middle
class (US$100–250) and poor (< US$100).
All patients underwent magnetic resonance imaging
(MRI) GE 1 Tesla (GE Healthcare, Chalfont St Giles,
Bucks, UK) prior to surgery and received gadolinium fol-
lowing certain protocols. The location of tumours was
recorded according to the respective lobes and sites.
Size of tumours was measured using the standard soft-
ware provided by the GE MRI machine. The consistencies
of tumours were reported by two blinded radiologists as
defined by a Japanese study.11 Calcification was detected
by computed tomography (CT) scan of the brain with a
Hounsfield value of between 100 and 300 H.U.12 Haemor-
rhage in the tumour was defined as any hyperdensity
(Hounsfield between 75 and 80 H.U.) measured using the
classical protocol. Midline shift was defined as any devia-
tion of the midline, taking the pineal gland as the centre.13
Vascularity was defined as any tumour blush seen on
MRI14 as seen by two blinded neuroradiologists. All
patients underwent total removal of tumours confirmed
by repeat CT scan with contrast within 24 hours of opera-
tion. If the tumour was still present, a reoperation was
done to remove all tumour, confirmed again by CT scan
of the brain with contrast. Treatment modalities were
chemotherapy, radiotherapy and immunotherapy as
requested and agreed by both radiation therapist/oncolo-
gist and patient. Recurrence on CT/MRI was defined as
any disease or lesion returning, or showing a tendency to
return from time to time, within the study period. Relapse
of signs and symptoms were defined as the reoccurrence
of symptoms similar to the previous complaint or signs
seen again on physical examination without the knowl-
edge of the radiological results.
PTEN mutations and LOH status were evaluated via
various methods mentioned below. Outcome was defined
as alive in good condition with a Karnofsky score of > 70,
alive in poor condition, being unable to care for oneself
completely with a score < 70 and dead.15
All patients were operated on and had a Karnofsky score
>70 prior to their inclusion in this study. All histopatholog-
ical examinations were reported according to the World
Health Organization (WHO) classification16 and seen by at
least three histopathologists and discussed in our neu-
ropathology conference, and all PTEN and LOH specimens
were analysed twice to rule out false or negative results.
Tumour specimens and DNA extraction
Thirty-seven specimens (human brain tumour tissues)
from individual patients referred to Universiti Sains
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Malaysia Hospital, Kelantan, Malaysia were collected. The
tumours were classified according to WHO classification
as eight astrocytoma (grade I), seven astrocytoma (grade
II), nine anaplastic astrocytoma (grade III), seven GBM
(grade IV), one oligodendroglioma, one ependymoma,
one pleomorphic xanthoastrocytoma, four anaplastic
oligodendroglioma and two anaplastic ependymoma.
Genomic DNA was extracted from human tumour tissues
using commercial extraction kits (QIAGEN Inc., Valencia,
CA, USA). Normal samples were extracted from blood
using commercial extraction kit (QIAGEN Inc.).
Polymerase chain reaction (PCR)–LOH analysis using
microsatellite markers
LOH was detected in DNA samples using highly poly-
morphic microsatellite markers on chromosomes 10q,
D10S532 (10q11), D10S541 (10q23) and D10S216 (10q25);
chromosomes 9p21, D9S165 (9p21) and D17S1176 and
chromosomes 13q12, D13S289 and D13S171 (Genome
Data Base). Nonradioactive PCR was performed in a reac-
tion mixture of 50 μL. Thirty cycles of PCR were performed
using Gradient Mastercycler (Eppendorf). PCR products
were loaded onto a denaturing polyacrylamide gel and
electrophoresed by using a sequencing gel apparatus. The
gel was then visualized by silver staining. All samples in
which two distinct alleles of similar intensity were pres-
ent in the normal DNA were considered to be informative.
LOH was scored as positive when there was a clear reduc-
tion of signal intensity (or more than 50%) detected in one
of the alleles of the tumour DNA compared with the
paired normal DNA.17
PCR–single-strand conformation polymorphism (SSCP)
analysis of PTEN gene
Prescreening for mutations on the PTEN gene was carried
out by PCR–SSCP analysis of exons 5, 6 and 8 using previ-
ously described primers.18 All PCR were performed with a
Gradient Mastercycler (Eppendorf) in 50 μL volume assays,
with 6% dimethyl sulfoxide for the primer sets of exon 5.
After an initial denaturation at 94°C for 3 minutes, 30 cycles
of denaturation (94°C for 1 minute), annealing (55°C for
the primer set of exon 5 and 58°C for the primer set of exons
6 and 8) and extension (72°C for 1 minute) were performed.
The final extension was performed for 10 minutes.
For PCR–SSCP analysis, 10 μL of heat-denatured sam-
ples of exon 6 were loaded onto a mutation detection
enhancement gel (FMC Corp., Rockland, ME, USA) 
containing 10% glycerol, while samples of exons 5 and 8 were
analysed using an 8% polyacrylamide gel containing 10%
glycerol. Gel electrophoresis was performed using sequenc-
ing gel apparatus (dCode™ BIORAD; Bio-Rad Laboratories,
Hercules, CA, USA) at 10–15 W for 16 hours. The tempera-
ture was maintained at 22°C using the apparatus. The gel
was then visualized by silver staining (modification of Echt
et al) after completion of electrophoresis. Samples that
showed mobility shifts or aberrant band patterns compared
to normal DNA were further analysed by the direct DNA
sequencing (BioSynTech Sdn Bhd, Selangor, Malaysia).
Survival analysis for survival time
The comparison of survival time between groups was
done by using log rank test. Univariate Cox proportional
hazards regression was applied to determine potential
prognostic factors of survival time. Level of significance
was set at 0.25 and variables that were less than 0.25 were
included in the multivariate analysis.
Multivariate Cox proportion regression was used to
identify prognostic factors of survival time of brain
tumour patients. Backward stepwise Cox regression was
used. Likelihood ratio (LR) test was applied to determine
significance of the model. The strength of association was
determined by hazards ratio with its 95% confidence
interval (CI). Log minus log plot and partial residual were
applied to check the proportional hazards assumption of
the final model. The results were presented by crude and
adjusted hazards ratio, 95% CI, LR statistic and p value.
Results
Patient characteristics
There were 37 patients admitted and followed up for 
3 years. The majority of patients were young (73% < 40
years old), with males being slightly more prevalent than
females. All the patients were Malays with no family his-
tory of tumour, and the majority were from low social
economic groups.
Among the four types of tumour, WHO grade III
gliomas were the most common (54.1%) and grade IV
gliomas were the least common (10.8%); 81% of patients
complained of headache, 48.6% had hemiplegia and 29.7%
had epilepsy.
Based on MRI or CT, 10.8% of patients had tumour
located in the left temporal lobe, 32.4% in the left frontal
and parietal lobe, 2.7% in the right temporal lobe, 13.5%
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in the right frontal and parietal lobe, and the rest were
located in other sites including cerebellum, fossa, mid-
brain, spine and medulla.
More than half (78.4%) of the tumours were > 2 cm in
size, and the remainder were ≤ 2 cm in size. Angiovascular-
ity was present in 62.2% of cases. Two modalities were
instituted for patients after surgery: radiotherapy (86.5%)
and chemotherapy (18.9%).
Follow-up was carried out after surgery; 59.5% of
patients were reported to be alive at more than 2 years
after surgery, while the remainder had died within 2 years
of surgery.
Identification of PTEN gene mutation
Of 37 gliomas analysed, seven (21.6%) showed mutations
in the PTEN gene. Of the seven detected mutations, two
were found in exon 5 (28.6%), three were found in exon 
6 (42.9%) and the other two (28.6%) were found in both
exons 5 and 6 (Table 1). Samples that showed presence 
of mobility shifts were sent for DNA sequencing and 
the results revealed the presence of single base substitu-
tion in all cases. Three of the seven cases (42.9%) caused
nonsense mutations and the other four cases (57.1%)
caused missense mutations. Among the base substitu-
tions, two cases were transition (G:C to A:C), three cases
caused stop codon to occur (C:A to T:A) and the other two
cases showed transition and transversion (G:T to C:T and
C:G to T:G).
Identification of LOH status
Out of 37 samples analysed, 12 (32.4%) showed LOH in
glioma cases. Of these 12 cases, one (8.3%) showed LOH
in chromosome 9p, four (33.3%) in chromosome 10q, two
(16.7%) in chromosome 13q, one (8.3%) in chromosome
17p, one (8.3%) in chromosomes 9p and 17q, one (8.3%)
in chromosomes 10q and 9p, one (8.3%) in chromosomes
10q and 17p, and one (8.3%) in chromosomes 10q, 9p and
17p (Table 1).
Descriptions of patients with PTEN
Seven patients were found to have PTEN mutations in
gliomas. Six patients were between the age of 1 and 40
years, and five of them were male. PTEN mutations were
detected in one patient with WHO grade II (14.3%), three
patients with grade III (42.9%) and three patients with
grade IV (42.9%). Three (42.9%) of the patients had
tumours located on the left side of the brain.
Four (57.1%) patients had epilepsy, four (57.1%) had
hemiplegia and all seven (100%) experienced headache.
Besides that, angiovascularity was present in all seven
patients.
Only four (57.1%) of the patients received chemother-
apy and the rest were not treated by either chemotherapy
or radiotherapy. Six out of seven patients were reported
to be alive for more than 2 years.
Descriptions of patients with LOH
Out of 12 reported LOH cases, seven (58.3%) were
younger than 40 years old and eight (66.7%) were male.
Out of 12 detected LOH, two were gliomas with WHO
grade II (16.7%), six (50%) were grade III and four (33.3%)
were tumours with grade IV. Eight (66.7%) of the patients
had tumours located on the left side of the brain.
Four out of 12 patients (33.3%) were reported to have
epilepsy, eight patients (66.7%) with hemiplegia and 11
(91.7%) of them experienced headache. Angiovascularity
was present in 11 patients (91.7%). Seven of the patients
(58.3%) received chemotherapy alone, two patients (16.7%)
received combination of both chemotherapy and radio-
therapy and three patients (25%) received neither chemo-
therapy nor radiotherapy.
Statistical analysis for survival time
For survival analysis, univariate Cox regression analysis
revealed that histopathological grade (HR = 9.01; 95% CI =
1.17, 69.12; p = 0.004), vascular (HR = 8.83; 95% CI = 1.15,
67.72; p = 0.005), PTEN (HR = 4.09; 95% CI = 1.42, 11.78;
p = 0.012), LOH (HR = 2.23; 95% CI = 1.11, 9.42; p = 0.031)
and combined presence of PTEN and LOH (HR = 7.11;
95% CI = 1.86, 27.18; p = 0.038) were significant prognos-
tic factors for the survival of patients with brain tumour
(Table 2). However, multivariate Cox proportional haz-
ards model indicate that no single variable was the prog-
nostic factor for survival (Table 3).
Discussion
Previous studies have reported that LOH at chromosome
10q23 and mutations of the tumour suppressor gene,
PTEN, occur at high frequency in a wide variety of human
tumours including gliomas.19,20
The most frequently documented regions of allelic
losses include 9p21, 10q23-25 and 17p13.21 In glioblas-
toma, LOH at 10q23 is detected in almost 70% of 
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the cases but they are rarely seen in low-grade glial
tumours.22,23
In gliomas, PTEN gene abnormalities are preferentially
found in high-grade gliomas, particularly in GBM.23–26
Deletions of the PTEN region at 10q23 are also reported as
predominant findings in glioblastoma.12,19,27 PTEN alter-
ations are detectable in a low fraction (< 10%) of anaplas-
tic astrocytomas and anaplastic oligodendrogliomas and,
when present, indicate a poor prognosis.28
Our results revealed that PTEN mutations and LOH
are frequent in gliomas, as reported in previous stud-
ies.22–26 The nonsense and missense mutations found in
glioma cases propose that truncated protein might be
produced due to the mutations, which could lead to brain
tumorigenesis. A study by Stahl has shown that loss of
PTEN normal growth regulation can significantly lead 
to tumour development.5 They investigated the develop-
ment of malignant melanoma and discovered that loss of
PTEN reduced apoptosis and promoted cell survival,
thereby favouring melanoma tumour formation.
Studying the association between biological and clini-
cal behaviours of gliomas may lead to improvement in pre-
dicting the clinical outcome of patients. PTEN gene and
LOH status of tumour patients may be potential markers
in molecular clinical research. This study was designed to
determine the prognostic significance of PTEN gene
mutations and LOH status in glioma patients and to cor-
relate them with certain parameters. In this study, we
analysed the mutational status of PTEN and LOH using
molecular techniques.
Balesaria et al found that there was a correlation
between any chromosome 10 loss and poorer performance
status at presentation (x2p = 0.005) and with increasing
age at diagnosis but not with tumour grade.9 Thus, they
suggested that LOH on chromosome 10 is an independ-
ent, adverse prognostic variable in high-grade glioma.
Similarly, Bower et al’s study demonstrated that LOH
on chromosome 10 is associated with reduced overall sur-
vival.10 Their study also revealed significant findings
between increasing age and poorer performance status at
presentation.
With regard to patient survival, univariate analysis
from our study shows that five parameters were associ-
ated with the survival rate of glioma patients, i.e. tumour
grade, vascularization, PTEN mutation, LOH and combi-
nation of both PTEN mutation and LOH. However, mul-
tivariate analysis revealed that no factors contributed to
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Table 2. Univariate Cox regression analysis of prognostic factors of brain tumour
Variable Hazards ratio (95% CI) LR test statistic p*
Age 1.54 (0.52, 4.61) 0.57 0.450
Sex 0.19 0.661
Male 1
Female 1.27 (0.44, 3.66)
HPE grade 8.18 0.004
Lower grade 1
Higher grade 9.01 (1.17, 69.12)
Epilepsy 0.73 0.392
No 1
Yes 0.59 (0.16, 2.11)
Hemiplegia 1.13 0.288
No 1
Yes 1.79 (0.60, 5.34)
Headache 0.25 0.619
No 1
Yes 1.44 (0.32, 6.43)
Site 3.46 0.178
Others 1
Nondominant 1.67 (0.28, 9.99)
Dominant 3.14 (0.85, 11.64)
Size 0.47 0.492
≤ 2 cm 1
> 2 cm 1.84 (0.37, 7.33)
Vascular 8.03 0.005
No 1
Yes 8.83 (1.15–67.72)
Chemotherapy 0.25 0.619
No 1
Yes 1.44 (0.32–6.43)
Radiotherapy 0.49 0.482
No 1
Yes 0.52 (0.07–3.99)
PTEN 6.36 0.012
No 1
Yes 4.09 (1.42–11.78)
LOH 4.63 0.031
No 1
Yes 2.23 (1.11–9.42)
Combined 8.44 0.038
LOH(–) PTEN(–) 1
LOH(–) PTEN(+) 3.72 (0.68–20.43)
LOH(+) PTEN(–) 2.62 (0.59–11.77)
LOH(+) PTEN(+) 7.11 (1.86–27.18)
*p value obtained from likelihood ratio test. CI = confidence interval; LR = likelihood ratio; LOH = loss of heterozygosity.
the survival outcome of the glioma patients. There is 
a possibility of finding a significant association if the
sample size is larger than the sample in this study. PTEN
mutations were only found in seven of 37 cases (18.9%)
and grades III and IV were found in 23 cases (62.2%). If the
mutations were found in a higher proportion of grades III
and IV tumours, there would have been a possibility of
obtaining significant association between tumour grade
and mutation.
Previous research have also shown that there are 
significant occurrences of gliomas with the presence of
gene mutation in the p53 gene. The p53 gene mutations
were reported to be significantly associated with the grade,
side and consistency of tumour.2 However, similar molec-
ular analysis of the p16 mutation revealed neither point
mutation nor homozygous deletion, suggesting that this
gene could not be involved and is not a common inac-
tivation mechanism in the pathogenesis of gliomas in
Malaysian patients.4
Our results showed that presence of PTEN mutations
and LOH did not play any prognostic role in Malaysian
patients. This may indicate that without PTEN mutations
and LOH, patients do not necessarily have a good prog-
nosis. From the results obtained, we conclude that other
genetic markers may play important roles in glioma prog-
nosis. Patients with PTEN mutations and presence of
LOH may need to be analysed for other markers before
receiving appropriate management of their tumours.
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